Focused On-demand Library for Translocon-associated protein subunit delta

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

P51571

UPID:

SSRD_HUMAN

Alternative names:

Signal sequence receptor subunit delta

Alternative UPACC:

P51571; A8K378; Q53XY1

Background:

The Translocon-associated protein subunit delta, also known as Signal sequence receptor subunit delta, plays a pivotal role in protein biosynthesis. It is part of the TRAP complex, crucial for binding calcium to the ER membrane, which in turn regulates the retention of ER resident proteins. This function is vital for proper protein folding and processing, impacting cell function and health.

Therapeutic significance:

The protein is linked to Congenital disorder of glycosylation 1Y, a multisystem disorder stemming from defects in glycoprotein biosynthesis. This association highlights the protein's critical role in embryonic development and cell function maintenance, suggesting that targeting this protein could lead to novel treatments for this congenital disorder and potentially other glycosylation-related diseases.